Guido Eibl

List of Publications by Year
in descending order

71 papers	3,752 citations	109321 35 h-index	128289 60 g-index
72 all docs	72 docs citations	72 times ranked	5611 citing authors

#	Article	IF	Citations
1	Statins inhibit inflammatory cytokine production by macrophages and acinar to ductal metaplasia of pancreatic cells. , 2022, , .		0
2	Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells. Pancreas, 2021, 50, 524-528.	1.1	7
3	Metformin: review of epidemiology and mechanisms of action in pancreatic cancer. Cancer and Metastasis Reviews, 2021, 40, 865-878.	5.9	20
4	Obesity and Pancreatic Cancer: Insight into Mechanisms. Cancers, 2021, 13, 5067.	3.7	25
5	Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. Cancers, 2021, 13, 5126.	3.7	18
6	Pancreatic Macrophages: Critical Players in Obesity-Promoted Pancreatic Cancer. Cancers, 2020, 12, 1946.	3.7	13
7	Endocrineâ€“exocrine signals in obesity-associated pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 455-456.	17.8	3
8	The Diverse Involvement of Cigarette Smoking in Pancreatic Cancer Development and Prognosis. Pancreas, 2020, 49, 612-620.	1.1	23
9	Nutritional Support and Probiotics as a Potential Treatment of IBD. Current Drug Targets, 2020, 21, 1417-1427.	2.1	6
10	Obesity-Induced Adipose Tissue Inflammation as a Strong Promotional Factor for Pancreatic Ductal Adenocarcinoma. Cells, 2019, 8, 673.	4.1	23
11	Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. World Journal of Gastroenterology, 2019, 25, 1797-1816.	3.3	17
12	Metformin alters the duodenal microbiome and decreases the incidence of pancreatic ductal adenocarcinoma promoted by diet-induced obesity. American Journal of Physiology - Renal Physiology, 2019, 317, G763-G772.	3.4	34
13	Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice. PLoS ONE, 2019, 14, e0216603.	2.5	34
14	Chemo-prevention and interception of obesity-promoted pancreatic ductal adenocarcinoma. , 2019, , 125-147.		0
15	Animal Models. Pancreas, 2019, 48, 759-779.	1.1	21
16	Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes. Pancreas, 2019, 48, 1-8.	1.1	16
17	KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Seminars in Cancer Biology, 2019, 54, 50-62.	9.6	55
18	Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival. Signal Transduction and Targeted Therapy, 2018, 3, 11.	17.1	112

#	Article	IF	Citations
19	Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model. Scientific Reports, 2018, 8, 5899.	3.3	34
20	Obesity and Pancreatic Cancer. Pancreas, 2018, 47, 158-162.	1.1	87
21	Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. Journal of the Academy of Nutrition and Dietetics, 2018, 118, 555-567.	0.8	91
22	Obesity Is Associated with Early Onset of Gastrointestinal Cancers in California. Journal of Obesity, 2018, 2018, 1-6.	2.7	21
23	Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice. Frontiers in Immunology, 2018, 9, 1229.	4.8	33
24	Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice. BMC Cancer, 2018, 18, 797.	2.6	15
25	Strategies to Prevent Obesity-Related Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 2442.	7.4	3
26	An Appraisal of Current Guidelines for Managing Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasm. JOP: Journal of the Pancreas, 2018, 19, 178-182.	1.5	1
27	Direct growth-inhibitory effects of prostaglandin E2 inÂpancreatic cancer cells inÂvitro through an EP4/PKA-mediated mechanism. Surgery, 2017, 161, 1570-1578.	1.9	7
28	Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes, 2017, 66, 1103-1110.	0.6	311
29	Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice. Frontiers in Immunology, 2017, 8, 1606.	4.8	18
30	Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. PLoS ONE, 2017, 12, e0184455.	2.5	107
31	Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. American Journal of Physiology - Renal Physiology, 2016, 310, G1124-G1137.	3.4	46
32	Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer. Pancreas, 2016, 45, 458-465.	1.1	43
33	Insulin promotes proliferation and fibrosing responses in activated pancreatic stellate cells. American Journal of Physiology - Renal Physiology, 2016, 311, G675-G687.	3.4	41
34	Long-term survival in patients with pancreatic ductal adenocarcinoma. Surgery, 2016, 159, 1520-1527.	1.9	77
35	Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1. American Journal of Physiology - Cell Physiology, 2015, 309, C639-C649.	4.6	31
36	E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma inÂmice. Surgery, 2015, 158, 1564-1572.	1.9	9

#	Article	IF	Citations
37	Models and Mechanisms of High-Fat Diet (HFD) Promotion of Pancreatic Cancer. Energy Balance and Cancer, 2015, , 197-215.	0.2	0
38	Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS ONE, 2014, 9, e114573.	2.5	61
39	Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 2980-2987.	4.1	54
40	miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2013, 439, 6-11.	2.1	64
41	The Flavonoid Quercetin Inhibits Pancreatic Cancer Growth In Vitro and In Vivo. Pancreas, 2013, 42, 223-229.	1.1	107
42	Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts. Pancreas, 2013, 42, 781-785.	1.1	75
43	High-Fat, High-Calorie Diet Promotes Early Pancreatic Neoplasia in the Conditional KrasG12D Mouse Model. Cancer Prevention Research, 2013, 6, 1064-1073.	1.5	127
44	Determination of Rottlerin, a Natural Protein Kinases C Inhibitor, in Pancreatic Cancer Cells and Mouse Xenografts by RP-HPLC Method. Journal of Chromatography & Separation Techniques, 2013, 4, .	0.2	8
45	Baicalein - An Intriguing Therapeutic Phytochemical in Pancreatic Cancer. Current Drug Targets, 2012, 13, 1772-1776.	2.1	78
46	Detection of Baicalin Metabolites Baicalein and Oroxylin-A in Mouse Pancreas and Pancreatic Xenografts. Pancreas, 2012, 41, 571-576.	1.1	39
47	The Phosphatase PHLPP1 Regulates Akt2, Promotes Pancreatic Cancer Cell Death, and Inhibits Tumor Formation. Gastroenterology, 2012, 142, 377-387.e5.	1.3	81
48	Overexpression of CXCL5 Is Associated With Poor Survival in Patients With Pancreatic Cancer. American Journal of Pathology, 2011, 178, 1340-1349.	3.8	147
49	Cyclooxygenase-2 Confers Growth Advantage to Syngeneic Pancreatic Cancer Cells. Pancreas, 2011, 40, 453-459.	1.1	13
50	Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1465-1474.	4.1	108
51	Epigenetic Regulation Affects N-myc Downstream-Regulated Gene 1 Expression Indirectly in Pancreatic Cancer Cells. Pancreas, 2010, 39, 675-679.	1.1	30
52	Loss of 15-Hydroxyprostaglandin Dehydrogenase Increases Prostaglandin E2 in Pancreatic Tumors. Pancreas, 2010, 39, 332-339.	1.1	22
53	Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. American Journal of Physiology - Renal Physiology, 2010, 298, G63-G73.	3.4	35
54	Bioluminescence Imaging of Angiogenesis in a Murine Orthotopic Pancreatic Cancer Model. Molecular Imaging and Biology, 2010, 12, 570-575.	2.6	20

#	Article	IF	Citations
55	Quercetin Aglycone Is Bioavailable in Murine Pancreas and Pancreatic Xenografts. Journal of Agricultural and Food Chemistry, 2010, 58, 7252-7257.	5.2	30
56	Metformin Disrupts Crosstalk between G Proteinâ€"Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth. Cancer Research, 2009, 69, 6539-6545.	0.9	293
57	Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery, 2008, 144, 57-65.	1.9	54
58	Expression Analysis of the Prostaglandin E2 Production Pathway in Human Pancreatic Cancers. Pancreas, 2008, 37, 121-127.	1.1	37
59	Opposing Effects of n-6 and n-3 Polyunsaturated Fatty Acids on Pancreatic Cancer Growth. Pancreas, 2008, 36, 353-362.	1.1	73
60	The Role of PPAR-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>and Its Interaction with COX-2 in Pancreatic Cancer. PPAR Research, 2008, 2008, 1-6.	2.4	32
61	Delayed Progression of Pancreatic Intraepithelial Neoplasia in a Conditional KrasG12D Mouse Model by a Selective Cyclooxygenase-2 Inhibitor. Cancer Research, 2007, 67, 7068-7071.	0.9	115
62	A Xenograft Nude Mouse Model for Perineural Invasion and Recurrence in Pancreatic Cancer. Pancreas, 2005, 31, 258-262.	1.1	45
63	Broad-Spectrum G Proteinâ€"Coupled Receptor Antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: A Dual Inhibitor of Growth and Angiogenesis in Pancreatic Cancer. Cancer Research, 2005, 65, 2738-2745.	0.9	95
64	Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Research, 2005, 65, 982-90.	0.9	48
65	COX and PPAR. Pancreas, 2004, 29, 247-253.	1.1	11
66	PGE2 is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2003, 306, 887-897.	2.1	112
67	The Selective Cyclooxygenase-2 Inhibitor Nimesulide Induces Apoptosis in Pancreatic Cancer Cells Independent of COX-2. Pancreas, 2003, 26, 33-41.	1.1	53
68	Endothelin A but Not Endothelin B Receptor Blockade Reduces Capillary Permeability in Severe Experimental Pancreatitis. Pancreas, 2002, 25, e15-e20.	1.1	17
69	Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block?. Intensive Care Medicine, 2002, 28, 139-146.	8.2	40
70	Peroxisome Proliferator-Activated Receptor Î³ Induces Pancreatic Cancer Cell Apoptosis. Biochemical and Biophysical Research Communications, 2001, 287, 522-529.	2.1	107
71	Endothelin receptor blockade in severe acute pancreatitis leads to systemic enhancement of microcirculation, stabilization of capillary permeability, and improved survival rates. Surgery, 2000, 128, 399-407.	1.9	74